Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 290

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead

Open access
Minard-Colin, Véronique, Brugières, Laurence, Reiter, Alfred, Cairo, Mitchell S., Gross, Thomas G., Woessmann, Wilhelm, Burkhardt, Birgit, Sandlund, John T., Williams, Denise, Pillon, Marta, Horibe, Keizo, Auperin, Anne, Le Deley, Marie-Cécile, Zimmerman, Martin, Perkins, Sherrie L., Raphael, Martine, Lamant, Laurence, Klapper, Wolfram, Mussolin, Lara, Poirel, Hélène A., Macintyre, Elizabeth, Damm-Welk, Christine, Rosolen, Angelo, Patte, Catherine·2015·Journal of Clinical Oncology

Abstract

Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in large part because of a better understanding of the biology of the different subtypes and national and international collaborations. Most patients with Burkitt lymphoma and diffuse large B-cell lymphoma are cured with short intensive pulse chemotherapy containing cyclophosphamide, cytarabine, and high-dose methotrexate. The benefit of the addition of rituximab has not been established except in the case of primary mediastinal B-cell lymphoma. Lymphoblastic lymphoma is treated with intensive, semi-continuous, longer leukemia-derived protocols. Relapses in B-cell and lymphoblastic lymphomas are rare and infrequently curable, even with intensive approaches. Event-free survival rates of approximately 75% have been achieved in anaplastic large-cell lymphomas with various regimens that generally include a short intensive B-like regimen. Immunity seems to play an important role in prognosis and needs further exploration to determine its therapeutic application. ALK inhibitor therapeutic approaches are currently under investigation. For all pediatric lymphomas, the intensity of induction/consolidation therapy correlates with acute toxicities, but because of low cumulative doses of anthracyclines and alkylating agents, minimal or no long-term toxicity is expected. Challenges that remain include defining the value of prognostic factors, such as early response on positron emission tomography/computed tomography and minimal disseminated and residual disease, using new biologic technologies to improve risk stratification, and developing innovative therapies, both in the first-line setting and for relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.5827

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 290

Metadata

Authors
Minard-Colin, V., Brugières, L., Reiter, A., Cairo, M. S., Gross, T. G., Woessmann, W., Burkhardt, B., Sandlund, J. T., Williams, D., Pillon, M., Horibe, K., Auperin, A., Le Deley, M.-C., Zimmerman, M., Perkins, S. L., Raphael, M., Lamant, L., Klapper, W., Mussolin, L., Poirel, H. A., Macintyre, E., Damm-Welk, C., Rosolen, A., & Patte, C.
Venue
Journal of Clinical Oncology
Published
2015-09-20
Volume
33
Issue
27
Pages
2963-2974
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2162244898
Cited by
290
References
39
FWCI
14.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. https://app.cochat.ai/papers/10.1200/jco.2014.59.5827
The paper
Minard-Colin, V., Brugières, L., Reiter, A., Cairo, M. S., Gross, T. G., Woessmann, W., Burkhardt, B., Sandlund, J. T., Williams, D., Pillon, M., Horibe, K., Auperin, A., Le Deley, M.-C., Zimmerman, M., Perkins, S. L., Raphael, M., Lamant, L., Klapper, W., Mussolin, L., . . . Patte, C. (2015). Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.59.5827

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.